We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Agenda - clinical presentation
- Categories of patients affected by IgAN
- Patients diagnosed accidentally
- Patients affected by macroscopic hematuria
- Patients with rapidly progressive renal disease
- Patients with IgAN recurrence after transplantation
- Patients with AKI due to macroscopic hematuria
- Factors influencing the disease evolution
- Typical courses of IgAN patients
- Histological presentation
- Time at diagnosis
- Variability in presentation and disease evolution
- Agenda - diagnosis
- Diagnosis
- Typical IgA staining in IgAN
- Agenda - prognosis
- Prognosis
- Markers for prognosis of IgAN
- Rationale for histological markers
- Histological classifications proposed
- Strength of oxford classification
- Weakness of the oxford classification
- Validation studies of oxford classification
- Potential biomarkers for IgAN
- Clinical prognostic markers
- Outcome and follow-up of proteinuria in IgAN
- Hypertension at diagnosis
- GFR decline
- Combination of different prognostic tools
- Prognostic factors (summary)
- Agenda - treatment
- General criteria
- KDIGO guidelines
- Supportive therapy
- Controversial non-immunosuppressive treatments
- Beneficial effect of the treatments
- Tonsillectomy across different studies
- Tonsillectomy and steroid treatment
- Tonsillectomy should not treat IgAN
- Corticosteroids in IgAN
- Open questions concerning steroid treatment
- Recent studies on the use of steroids in low GFR
- Other immunosuppressants: Azathioprine
- Other immunosuppressants: MMF
- KDIGO position
- Suggested therapeutic approach to IgAN
- Ongoing clinical trials (1)
- Ongoing clinical trials (2)
- Thank you
Topics Covered
- Clinical presentation of IgA Nephropathy
- Disease evolution
- Histological presentation
- Diagnosis
- Prognosis
- Histological markers
- Oxford classification
- Prognostic markers
- Treatment
- Non-immunosuppressive treatment
- Steroid treatment
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Salvadori, M. (2016, August 31). What’s new for IgA nephropathy part 2: clinical presentation, diagnosis, prognosis, treatment [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 3, 2024, from https://doi.org/10.69645/UTNA4471.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Maurizio Salvadori has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
What’s new for IgA nephropathy part 2: clinical presentation, diagnosis, prognosis, treatment
Published on August 31, 2016
23 min
Other Talks in the Series: The Kidney in Health and Disease
Transcript
Please wait while the transcript is being prepared...
0:00
This is my second presentation
on IgA Nephropathy.
I'm Professor Salvadori
from the University of Florence.
0:12
This time
I will discuss with you
the second part
of IgA nephropathy.
That is
the clinical presentation,
the diagnosis, the prognosis
and finally the treatment.
This will be the agenda
of my presentation.
But let me start
with the clinical presentation.
0:36
Overall there are
five different categories
of patients that are affected
by IgA nephropathy
with different
clinical presentations.
There are patients
who are diagnosed accidentally,
with no symptoms.
Patients affected
by a recurrent
macroscopic hematuria.
Patients with rapidly
progressive renal disease.
Patients with
IgA nephropathy recurrence
after kidney transplantation.
And finally,
patients
with acute kidney injury
due to macroscopic hematuria.
1:18
Patients diagnosed accidentally,
they are often found
while looking
for clinical manifestations
such as reduced a
glomerular filtration rate,
hypertension,
or urinary abnormalities.
These patients represent
the silent majority.
1:39
The second patients
are those affected
by macroscopic hematuria.
Patients affected
by macroscopic hematuria,
often recur the hematuria
after acute infective disease,
occurred in
the upper respiratory tract.
These patients are called
the typical IgA
nephropathy patients.
Hide